Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

6533b7d8fe1ef96bd126aeb6

RESEARCH PRODUCT

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Antonio Solana-altabella Pau Montesinos José Luis Piñana Rebeca Rodríguez-veiga Maria Luz Amigo Cristina Gil María López-pavía David Martínez-cuadrón Maria Jose Sayas Miguel A. Sanz Albert Blanco Evelyn Acuña-cruz Lorenzo Algarra Juan Eduardo Megías-vericat Aurelio López Blanca Boluda Eva Barragán Mar Tormo Rosalía Delapuerta Javier Marco-ayala Isabel Cano Claudia Sargas Raimundo García Alvaro Díaz-gonzález

subject

Oncology Adult Cancer Research medicine.medical_specialty real-world *real-world 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine *FLT3mut AML Humans Patterns of care relapse Salvage Therapy Adult patients FLT3mut AML business.industry FLT3mut AML real-world relapse/refractory Remission Induction Cytarabine Myeloid leukemia Hematology *relapse/refractory refractory Leukemia Myeloid Acute Treatment Outcome Oncology fms-Like Tyrosine Kinase 3 030220 oncology & carcinogenesis Relapsed refractory business 030215 immunology

description

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 30% with non-intensive p = 0.005). Median overall survival since first R/R was 5.8 months, and 16.3 months in subjects receiving an allo-HSCT in CR/CRi after first salvage (vs 3.8 in the remaining patients p < 0.0001). Clinical outcomes of R/R FLT3mut AML remain unsatisfactory. Inclusion in clinical trials and expanding options could lead to improved outcomes.

year	journal	country	edition	language
2021-01-01	Leukemialymphoma

10.1080/10428194.2021.1938031 https://pubmed.ncbi.nlm.nih.gov/34121593